Aduro Biotech Receives Orphan Drug Designation in the European Union for CRS-207 for the Treatment of Mesothelioma
November 23, 2015 at 08:01 AM EST
Aduro Biotech, Inc. (Nasdaq: ADRO) today announced that the European Medicines Agency (EMA) granted Orphan Drug Designation to CRS-207 ...